Market Cap | 15.70B | P/E | 44.69 | EPS this Y | - | Ern Qtrly Grth | -95.40% |
Income | 183.35M | Forward P/E | 22.42 | EPS next Y | 11.60% | 50D Avg Chg | 5.00% |
Sales | 2.73B | PEG | 2.57 | EPS past 5Y | 8.78% | 200D Avg Chg | -3.00% |
Dividend | N/A | Price/Book | 1.99 | EPS next 5Y | 8.57% | 52W High Chg | -24.00% |
Recommedations | 2.20 | Quick Ratio | 1.66 | Shares Outstanding | 123.53M | 52W Low Chg | 13.00% |
Insider Own | 0.28% | ROA | 1.53% | Shares Float | 111.71M | Beta | 1.09 |
Inst Own | 88.08% | ROE | 2.31% | Shares Shorted/Prior | 3.60M/3.17M | Price | 125.12 |
Gross Margin | 55.52% | Profit Margin | 5.49% | Avg. Volume | 878,546 | Target Price | 125.98 |
Oper. Margin | 8.55% | Earnings Date | Jul 30 | Volume | 1,341,776 | Change | 2.03% |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Baird | Outperform | Apr 30, 24 |
TD Cowen | Buy | Apr 30, 24 |
Stifel | Hold | Feb 2, 24 |
Keybanc | Overweight | Feb 2, 24 |
Raymond James | Outperform | Feb 2, 24 |
Barclays | Equal-Weight | Jan 25, 24 |
UBS | Neutral | Jan 16, 24 |
Evercore ISI Group | Outperform | Jan 4, 24 |
Wells Fargo | Equal-Weight | Dec 19, 23 |